Serum Institute of India: News

Serum Institute seeks DCGI's approval for Covovax as booster dose

The Serum Institute of India (SII) has sought the Drugs Controller General of India's (DCGI) approval to roll out its Covovax in the market as a booster dose for adults.

29 Nov 2022

Gautam Adani

India's 100 richest amassed $25bn more wealth in 2022: Forbes

While the rupee has weakened, raising concerns of inflation and looming recession for the rest of the Indians, it has seemingly no effect on the country's richest bunch.

26 Nov 2022

Pune

Covishield manufacturer SII duped of Rs. 1 crore, 7 arrested

In a major cheating and cyber fraud case, the Serum Institute of India (SII) has been duped of Rs. 1 crore.

03 Sep 2022

Bombay High Court

Covishield death: Bombay HC notice to Centre, Serum Institute, DCGI

A man has filed a compensation suit against the Indian vaccine maker Serum Institute of India (SII) for Rs. 1,000 crore, claiming that the side effects of the Covishield vaccine killed his daughter last year.

31 Aug 2022

Cancer

India to get its first indigenous cervical cancer vaccine today

India is all set to get its first indigenous cervical cancer vaccine this week.

26 Jul 2022

Vaccine

Is SII developing vaccine for monkeypox? Here's what Poonawalla said

Amid the rising monkeypox scare, Serum Institute of India (SII) CEO Adar Poonawalla said on Tuesday they are in talks with American biotech company Novavax to develop a messenger RNA (mRNA) vaccine for it.

29 Apr 2022

Vaccine

India inching closer to launching its first dengue vaccine

India is likely to get its first vaccine for dengue soon as the Indian Council of Medical Research (ICMR) is all set to submit its clinical trial protocol to the country's drug regulator CDSCO by June.

09 Apr 2022

COVID-19

COVID-19 vaccine precautionary dose service charge capped at Rs. 150

The Centre on Saturday announced that private vaccination centers can charge a service fee of up to Rs. 150 in addition to the cost of the precautionary dose of the COVID-19 vaccine from beneficiaries.

09 Mar 2022

Vaccine

DCGI approves emergency use of Covovax in children above 12

The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation to the coronavirus vaccine Covovax for restricted emergency use in children above the age of 12.

07 Mar 2022

Vaccine

Govt panel okays phase-3 trials of Covovax as booster dose

The subject expert committee (SEC) of India's drug regulatory authority Central Drugs Standard Control Organization (CDSCO) has recommended phase-3 clinical trials of Covovax as a booster dose against COVID-19 in adults, Mint reported.

Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla

Billions need to be vaccinated at a faster rate to reach the end of the COVID-19 pandemic, said Adar Poonawalla, CEO of the Serum Institute of India (SII), which manufactures the COVID-19 vaccine Covishield.

15 Dec 2021

Adar Poonawalla

SII to launch COVID-19 vaccine for children in 6 months

The Serum Institute of India is looking to launch a COVID-19 vaccine for children in six months, SII CEO Adar Poonawalla said Tuesday.

03 Dec 2021

Pfizer

COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective

Seven COVID-19 vaccines are safe and stimulate a strong immune response when used as a booster jab to those who have already vaccinated, a study published in The Lancet said.

01 Dec 2021

Zydus Cadila

Are Indian vaccines effective against Omicron? Here's what manufacturers say

The COVID-19 vaccine manufacturers in India are reportedly waiting for "more data" on the new coronavirus variant, Omicron, to assess the efficacy of their vaccines.

Serum gets nod for Novavax trial in 7-11 age group

The Serum Institute of India (SII) has received the approval to conduct trials of the Novavax COVID-19 vaccine in children aged between seven and 11 years.

14 Aug 2021

Covishield

SII's Poonawalla bats for booster dose, opposes mixing of vaccines

Serum Institute of India Chairman Cyrus Poonawalla on Friday said that taking a third or booster dose of Covishield, the coronavirus vaccine manufactured by his firm was desirable.

17 Jul 2021

Europe

EU body says it didn't receive application for Covishield approval

The European Medicines Agency (EMA) said it has not received any application for the authorization of the coronavirus vaccine Covishield.

13 Jul 2021

Coronavirus

COVID-19: Serum to start producing Sputnik V vaccine from September

The Serum Institute of India (SII) will begin producing the Russian COVID-19 vaccine, Sputnik V, from September, the Russian Direct Investment Fund (RDIF) announced today.

Expert panel says no to Covovax's children trials in India

A Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has denied permission to Pune-based Serum Institute of India (SII) for conducting clinical trials of its second COVID-19 vaccine, Covovax, in children.

'Not received Covishield approval request,' says EU body amid concerns

The Serum Institute of India (SII) has not yet applied for the approval of its coronavirus vaccine Covishield in the "Green Pass" issued by the European Union, according to a statement from the EU.

26 Jun 2021

Coronavirus

Serum to begin Covovax trials on children in July

The Serum Institute of India (SII) will soon apply for regulatory approval to conduct clinical trials of Covovax on children in India.

Efforts on to restart AstraZeneca shipments from India: WHO official

The WHO is urgently trying to work with AstraZeneca, Serum Institute of India (SII) as well as the Indian government to restart shipments of COVID-19 vaccines to countries, a senior official at the UN health agency said.

17 Jun 2021

Vaccine

Covovax India launch by September; trial for kids soon: SII

The Serum Institute of India (SII) is looking to launch the COVID-19 vaccine developed by the United States firm Novavax in India by September.

03 Jun 2021

Pfizer

After Pfizer and Moderna, Serum seeks indemnity over COVID-19 vaccine

The Serum Institute of India has requested the Indian government to provide it indemnity from liability in connection with its COVID-19 vaccines, company sources cited by NDTV and The Hindu say.

28 May 2021

Aam Aadmi Party (AAP)

Centre creating 'artificial scarcity' of COVID-19 vaccines: AAP

The AAP on Friday alleged that the Centre is creating artificial scarcity of COVID-19 vaccines to benefit Bharat Biotech and Serum Institute of India, a charge termed by the Delhi BJP as unfounded.

13 May 2021

Vaccine

Government panel recommends 12-16 week gap between Covishield doses

A government expert panel has reportedly recommended raising the time gap between two doses of the COVID-19 vaccine Covishield to 12-16 weeks.

13 May 2021

Government of India

Coronavirus vaccine production to reach 9cr doses in June: Government

The Serum Institute of India and Bharat Biotech, the two companies India has entrusted to make its coronavirus vaccines, have both submitted their productions plans for the coming four months to the Indian government.

12 May 2021

Vaccine

US looking to produce of J&J's COVID-19 vaccine in India

The United States is considering the production of Johnson & Johnson's COVID-19 vaccine in India along with ways to help manufacturers like the Serum Institute of India (SII) to boost production, Daniel B Smith, Charge d'Affaires of the US Embassy, said on Tuesday.

04 May 2021

Maharashtra

Give priority to Maharashtra in vaccine allocation: Tope to Poonawalla

Maharashtra Health Minister Rajesh Tope on Monday urged Serum Institute of India Chief Executive Officer Adar Poonawalla to give priority to the state in providing its anti-coronavirus vaccine, Covishield, as the government was ready to purchase doses from the Pune-based company.

03 May 2021

India

SII given over Rs. 1,700cr for 11cr Covishield doses: Centre

The Health Ministry on Monday said that a 100 percent advance of Rs. 1732.50 crore was released to the Serum Institute of India on April 28 for 11 crore doses of Covishield vaccine during May, June, and July.

02 May 2021

Vaccine

Getting aggressive calls from powerful people: SII CEO Adar Poonawalla

Serum Institute of India CEO Adar Poonawalla has revealed that his decision to fly to London when India is facing a COVID-19 second wave was largely due to the threats he had been facing.

28 Apr 2021

Vaccine

Covishield price reduced to Rs. 300 for states: Adar Poonawalla

Adar Poonawalla, the CEO of the Serum Institute of India (SII), on Wednesday announced that the price of the COVID-19 vaccine Covishield was being reduced from Rs. 400 to Rs. 300 for states.

27 Apr 2021

Government of India

COVID-19: Government asks SII, Bharat Biotech to cut vaccine prices

The central government has asked the Serum Institute of India (SII) and Bharat Biotech to reduce the prices of their COVID-19 vaccines, PTI reported on Monday.

21 Apr 2021

Coronavirus

SII fixes Covishield's price at Rs. 600 for private hospitals

Serum Institute of India (SII) will sell Covishield at Rs. 400 per shot to states and at Rs. 600 to private hospitals, the Pune-based vaccine manufacturer said today.

We understand India's pharmaceutical requirements: Biden administration

The Biden administration has conveyed to New Delhi that it understands India's pharmaceutical requirements and promised to give the matter due consideration, observing that the current difficulty in the export of critical raw materials needed to manufacture COVID-19 vaccines is mainly due to an Act that forces American companies to prioritize domestic consumption.

09 Apr 2021

South Africa

India's Serum Institute refunds South Africa for undelivered coronavirus vaccines

Pune-based Serum Institute of India (SII) has fully refunded South Africa for 500,000 undelivered doses of the coronavirus vaccine, reports PTI.

08 Apr 2021

Adar Poonawalla

AstraZeneca serves legal notice to Serum Institute over vaccine delays

Serum Institute of India (SII), the manufacturer of the coronavirus vaccine Covishield, has been served a legal notice by the drug maker AstraZeneca over delays in vaccine supply, the company's CEO Adar Poonawalla confirmed in an interview earlier this week.

06 Apr 2021

Vaccine

Covishield 90% effective if doses given 2-3 months apart: Poonawalla

The efficacy of the COVID-19 vaccine Covishield could increase to 90% if the two doses are given 2.5-3 months apart, Serum Institute of India CEO Adar Poonawalla said Monday.

27 Mar 2021

Adar Poonawalla

Serum CEO Poonawalla hopes to launch second vaccine by September

Serum Institute of India CEO Adar Poonawalla today said that his company hopes to launch its second coronavirus vaccine by September this year.

25 Mar 2021

Vaccine

Amid growing cases, India temporarily halts export of AstraZeneca's vaccine

Facing a sudden spike in coronavirus cases, India has halted the export of the AstraZeneca vaccine for now, Reuters reported quoting two sources. Millions of doses of the vaccine are being manufactured by the Pune-based Serum Institute of India (SII), the world's biggest vaccine-maker.

Prev
1 2 3
Next